Maintaining bone health in patients with multiple myeloma: Survivorship care plan of the international myeloma foundation nurse leadership board

Clinical Journal of Oncology Nursing

Volumn 15, Issue SUPPL., 2011, Pages 9-23

  Miceli, Teresa S ^a   Colson, Kathleen ^b   Faiman, Beth M ^c   Miller, Kena ^d   Tariman, Joseph D ^e  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE; BONE TUMOR; HUMAN; LEADERSHIP; METASTASIS; MULTIPLE MYELOMA; NURSING; PATHOPHYSIOLOGY; QUALITY OF LIFE; RISK FACTOR; SCINTISCANNING; SURVIVOR;

BONE AND BONES; BONE NEOPLASMS; HUMANS; LEADERSHIP; MULTIPLE MYELOMA; QUALITY OF LIFE; RISK FACTORS; SURVIVORS;

EID: 80053085595     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/11.S1.CJON.9-23     Document Type: Article

References (76)

1. Adami S. (2009). Bone health in diabetes: Considerations for clinical management. Current Medical Research and Opinion, 25, 1057-1072. doi:10.1185/03007990902801147
2. Aloia, J.F. (2008). African Americans, 25-hydroxyvitamin D, and osteoporosis: A paradox. American Journal of Clinical Nutrition, 88, 545S-550S.
3. Angtuaco, E.J., Fassas, A.B., Walker, R., Sethi, R., & Barlogie, B. (2004). Multiple myeloma: Clinical review and diagnostic imaging. Radiology, 231, 11-23. doi:10.1148/radiol.2311020452
4. Awan, N., Azer, A., Harrani, K., & Cogley, D. (2002). Intramedullary spread of tumour cells during IM nailing: A histological diagnosis. European Journal of Orthopaedic Surgery and Traumatology, 12, 53-55. doi:10.1007/s00590-002-0013-x
5. Bartel, T.B., Haessler, J., Brown, T.L., Shaughnessy, J.D., Jr., van Rhee, F., Anaissie, E., Barlogie, B. (2009). F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood, 114, 2068-2076. doi:10.1182/blood-2009-03-213280
6. Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schedchtmann, K., Tillman, J.T., the Cancer Patient Fracture Evaluation Investigators. (2011). Balloon kyphoplasty versus nonsurgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomized controlled trial. Lancet Oncology. Advanced online publication. doi:10.1016/S1470-2045(11)70008-0
7. Berenson, J.R., Rajdev, L., & Border, M. (2006). Bone complications in multiple myeloma. Cancer Biology and Therapy, 5, 1082-1085.
8. Berkey, F.J. (2010). Managing the adverse effects of radiation therapy. American Family Physician, 82, 381-388.
9. Bischoff-Ferrari, H.A. (2007). The 25-hydroxyvitamin D threshold for better health. Journal of Steroid Biochemistry and Molecular Biology, 103(3-5), 614-619. doi:10.1016/j.jsbmb.2006.12.016
10. Bolzoni, M., Abeltino, M., Storti, P., Bonomini, S., Agnelli, L., Todoerti, K., Giuliani, N. (2010). The immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and RANKL/OPG ratio in myleoma microenvironment targeting the expression of adhesion molecules [Abstract 448]. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper29811.html
11. Breitkreutz, I., Raab, M.S., Vallet, S., Hideshima, T., Raje, N., Mitsiades, C., Anderson, K.C. (2008). Lenalidomide inhibits osteoclastogenesis, survival factors, and bone-remodeling markers in multiple myeloma. Leukemia, 22, 1925-1932. doi:10.1038/leu.2008.174
12. Cady, B., Easson, A., Aboulafia, A.J., & Ferson, P.F. (2005). Part 1: Surgical palliation of advanced illness-What's new, what's helpful. Journal of the American College of Surgeons, 200, 115-127. doi:10.1016/j.jamcollsurg.2004.10.007
13. Cafro, A.M., Barbarano, L., Nosari, A.M., D'Avanzo, G., Nichelatti, M., Bibas, M., Andriani, A. (2008). Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Definition and management of the risk related to zoledronic acid. Clinical Lymphoma and Myeloma, 8, 111-116. doi:10.3816/CLM.2008.n.013
14. Cashman, K.D. (2007). Diet, nutrition, and bone health. Journal of Nutrition, 137(11, Suppl.), 2507S-2512S.
15. Chau, D.L., & Edelman, S.V. (2002). Osteoporosis and diabetes. Clinical Diabetes, 20, 153-157. doi:10.2337/diaclin.20.3.153
16. Coleman, R.E. (2000). Management of bone metastases. Oncologist, 5, 463-470. doi:10.1634/theoncologist.5-6-463
17. Coleman, R.E. (2001). Metastatic bone disease: Clinical features, pathophysiology, and treatment strategies. Cancer Treatment Reviews, 27(3), 165-176. doi:10.1053/ctrv.2000.0210
18. Coleman, R.E. (2006). Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research, 12(20, Pt. 2), 6243S-6249S. doi:10.1158/1078-0432.CCR-06-0931
19. Dimopoulos, M.A., Moulopoulos, L.A., & Terpos, E. (2009). A new pet for myeloma. Blood, 114, 2007-2008. doi:10.1182/blood-2009-06-224196
20. Durie, B.G., & Salmon, S.E. (1975). A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer, 36, 842-854. doi:10.1002/1097-0142(197509) 36:3<842::AID-CNCR2820360303>3.0.CO;2-U
21. Durie, B.G.M. (2006). The role of anatomic and functional staging in myeloma: Description of Durie/Salmon PLUS staging system. European Journal of Cancer, 42, 1539-1543. doi:10.1016/j.ejca.2005.11.037
22. Durie, B.G.M., Attal, M., Beksac, M., Belch, A., Bensinger, W., Blade, J., Zonder, J. (2007). Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clinic Proceedings, 82, 516-517. doi:10.4065/82.4.516
23. Ebeling, P.R., Thomas, D.M., Erbas, B., Hopper, J.L., Szer, J., & Grigg, A.P. (1999). Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. Journal of Bone Mineral Research, 14, 342-350. doi:10.1359/jbmr.1999.14.3.342
24. Epstein, J., & Walker, R. (2006). Myeloma and bone disease: "The dangerous tango. "Clinical Advances in Hematolology and Oncology, 4, 300-306.
25. Esteve, F.R., & Roodman, G.D. (2007). Pathophysiology of myeloma bone disease. Best Practice in Research and Clinical Haematology, 20, 613-624. doi:10.1016/j.beha.2007.08.003
26. Everitt, A.V., Hilmer, S.N., Brand-Miller, J.C., Jamison, H.A., Truswell, A.S., Sharma, A.P., Le Couteur, D.G. (2006). Dietary approaches that delay age-related diseases. Clinical Interventions in Aging, 1, 11-31. doi:10.2147/ciia.2006.1.1.11
27. Faiman, B., Bilotti, E., Mangan, P.A., Rogers, K., & The International Myeloma Foundation Nurse Leadership Board. (2008). Consensus statement for the management of steroid-associated side effects in patients with multiple myeloma. Clinical Journal of Oncology Nursing, 12(3, Suppl.), 53-62. doi:10.1188/08.CJON.S1.53-62
28. Faiman, B., Mangan, P.A., Spong, J., Tariman, J.D., & the International Myeloma Foundation Nurse Leadership Board. (2011). Renal complications in multiple myeloma and related disorders: Survivorship care plan of the International Myeloma Foundation Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(4, Suppl.), 66-76.
29. Fitch, M.I., & Maxwell, C. (2008). Bisphosphonate therapy for metastatic bone disease: The pivotal role of nurses in patient education. Oncology Nursing Forum, 35, 709-713. doi:10.1188/08.ONF.709-713
30. Golden, E.B., Lam, P.Y., Kardosh, A., Gaffney, K.J., Cadenas, E., Louie, S.G., Schonthal, A.H. (2009). Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 113, 5927-5937. doi:10.1182/blood-2008-07-171389
31. Greipp, P.R., San Miguel, J., Durie, B.G.M., Crowley, J.J., Barlogie, B., Blade, J., Westin, J. (2005). International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 3412-3420. doi:10.1200/JCO.2005.04.242
32. Guise, T.A. (2006). Bone loss and fracture risk associated with cancer therapy. Oncologist, 11, 1121-1131.
33. Hu, K., & Yahalom, J. (2000). Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park), 14, 101-108.
34. Kang, M.I., Lee, W.Y., Oh, K.W., Han, J.H., Song, K.H., Cha, B.Y., Kim, C.C. (2000). The short-term changes of bone mineral metabolism following bone marrow transplantation. Bone, 26, 275-279. doi:10.1016/S8756-3282(99)00265-3
35. Kanis, J.A., & McCloskey, E.V. (2000). Bisphosphonates in multiple myeloma. Cancer, 88(12, Suppl.), 3022-3032. doi:10.1002/1097-0142(20000615)88:12+<3022::AID-CNCR19>3.0.CO;2-R
36. Kerschan-Schindl, K., Mitterbauer, M., Fureder, W., Kudlacek, S., Grampp, S., Bieglmayer, C., Kalhs, P. (2004). Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant, 34, 491-496. doi:10.1038 /sj.bmt.1704618
37. Kielholz, U., Max, R., Scheibenbogen, C., Wuster, C., Korbling, M., & Haas, R. (1997). Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation. Cancer, 79, 1617-1622.
38. Kyle, R.A., Child, J.A., Anderson, K., Barlogie, B., Bataille, R., Bensinger, W., the International Myeloma Working Group. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: A report of the International Myeloma Working Group. British Journal of Haematology, 121, 749-757. doi:10.1046/j.1365-2141.2003.04355.x
39. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Greipp, P.R. (2003). Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21-33. doi:10.4065/78.1.21
40. Kyle, R.A., & Rajkumar, S.V. (2007). Epidemiology of the plasma-cell disorders. Best Practice and Research Clinical Hematology, 20, 637-664. doi:10.1016/j.beha.2007.08.001
41. Kyle, R.A., Schreiman, J.S., McLeod, R.A., & Beabout, J.W. (1985). Computed tomography in diagnosis and management of multiple myeloma and its variants. Archives of Internal Medicine, 145, 1451-1452. doi:10.1001/archinte.145.8.1451
42. Kyle, R.A., Yee, G.C., Somerfield, M.R., Flynn, P.J., Halabi, S., Jagannath, S., Anderson, K. (2007). American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. Journal of Clinical Oncology, 25, 2464-2672. doi:10.1200/JCO.2007.12.1269
43. Lee, W.Y., Cho, S.W., Oh, E.S., Oh, K.W., Lee, J.M., Yoon, K.H., Kim, C.C. (2002). The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. Journal of Clinical Endocrinology and Metabolism, 87, 329-335. doi:10.1210/jc.87.1.329
44. Lee, W.Y., Kang, M.I., Baek, K.H., Oh, E.S., Oh, K.W., Lee, K.W., Kim, C.C. (2002). The skeletal site-differential changes in bone mineral density following bone marrow transplantation: Three-year prospective study. Journal of Korean Medical Sciences, 17, 749-754.
45. Legg, V. (2005). Complications of chronic kidney disease. American Journal of Nursing, 105(6), 40-49.
46. Levy, M.H. (1996). Pharmacologic treatment of cancer pain. New England Journal of Medicine, 335, 1124-1132. doi:10.1056/NEJM199610103351507
47. Ludwig, H., & Zojer, N. (2007). Supportive care in multiple myeloma. Best Practice and Research in Clinical Haematology, 20, 817-835. doi:10.1016/j.beha.2007.10.001
48. Mariette, X., Zagdanski, A.M., Guermazi, A., Bergot, C., Arnould, A., Frija, J., Fermand, J.P. (1999). Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. British Journal of Haematology, 104, 723-729. doi:10.1046/j.1365-2141.1999.01244.x
49. Mauck, K.F., & Clarke, B.L. (2006). Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clinic Proceedings, 81, 662-672. doi:10.4065/81.5.662
50. Maxwell, C., Swift, R., Goode, M., Doane, L., & Rogers, M. (2003). Advances in supportive care of patients with cancer and bone metastasis: Nursing implications of zoledronic acid. Clinical Journal of Oncology Nursing, 7, 403-408. doi:10.1188/03.CJON.403-408
51. Melton, L.J., III, Kyle, R.A., Achenbach, S.J., Oberg, A.L., & Rajkumar, S.V. (2005). Fracture risk with multiple myeloma: A population-based study. Journal of Bone and Minereral Research, 20, 487-493. doi:10.1359/JBMR.041131
52. Mezuk, B., Eaton, W.W., & Golden, S.H. (2008). Depression and osteoporosis: Epidemiology and potential mediating pathways. Osteoporosis International, 9, 1-12. doi:10.1007/s00198-007-0449-2
53. Mezuk, B., Eaton, W.W., Golden, S.H., Wand, G., & Lee, H.B. (2008). Depression, antidepressants, and bone mineral density in a population-based cohort. Journal of Gerontology A, Biologic Science and Medical Science, 63, 1410-1415.
54. Montefusco, V., Gay, F., Spina, F., Miceli, R., Maniezzo, M., Ambrosini, M.T., Corradini, P. (2008). Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia and Lymphoma, 49, 2156-2162. doi:10.1080/10428190802483778
55. Morgan, G.J., Davies, F.E., Gregory, W.M., Cocks, K., Bell, S.E., Szubert, A.J., the National Cancer Research Institute Haematological Oncology Clinical Study Group. (2010). First-line treatment with zoledronic acid as compared with clodonic acid in multiple myeloma (MRC Myeloma IX): A randomized controlled trial. Lancet, 376, 1989-1999. doi:10.1016/S0140-6736(10)62051-X
56. National Comprehensive Cancer Network. (2010). Clinical Practice Guidelines in Oncology™: Multiple myeloma [v.3.2010]. Retrieved from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
57. National Osteoporosis Foundation. (2010). Fast facts on osteoporosis, 2010. Retrieved from http://www.nof.org/osteoporosis/diseasefacts.htm#top
58. Pennisi, A., Li, X., Ling, W., Khan, S., Zangari, M., & Yaccoby, S. (2009). The proteasome inhibitor, bortezomib, suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. American Journal of Hematology, 84, 6-14. doi:10.1002/ajh.21310
59. Rome, S., Jenkins, B., Lilleby, K., & the International Myeloma Foundation Nurse Leadership Board. (2011). Mobility and safety in the multiple myeloma survivor: Survivorship care plan of the IMF Nurse Leadership Board. Clinical Journal of Oncology Nursing, 15(4, Suppl.), 41-52.
60. Roodman, G.D. (2004). Mechanisms of bone metastasis. New England Journal of Medicine, 350, 1655-1664. doi:10.1056/NEJMra030831
61. Roodman, G.D. (2008). Skeletal imaging and management of bone disease. Hematology: American Society of Hematology Education Program, 313-319.
62. Sezer, O. (2009). Myeloma bone disease: Recent advances in biology, diagnosis, and treatment. Oncologist, 14, 276-283. doi:10.1634/theoncologist.2009-0003
63. Steinberg, J.A., Shen, J., Sanchez, E., Chen, H., Li, Z.W., Hilger, J., & Berenson, J.R., (2009). Alpha lipoic acid (ALA) inhibits the antimyeloma effects of bortezomib [Abstract 3832]. Retrieved from http://ash.confex.com/ash/2009/webprogram/Paper19795.html
64. Szulc, P., Kiel, D.P., & Delmas, P.D. (2008). Calcifications in the abdominal aorta predict fractures in men: MINOS study. Journal of Bone and Mineral Research, 23, 95-102. doi:10.1359/jbmr.070903
65. Tariman, J., & Faiman, B. (2011). Multiple myeloma. In C.H. Yarbro, D. Wujcik, & B.H. Gobel (Eds.), Cancer nursing principles and practice (7th ed., pp. 1513-1545). Boston, MA: Jones and Bartlett.
66. Tariman, J.D., & Estrella, S.M. (2005). The changing treatment paradigm in patients with newly diagnosed multiple myeloma: Implications for nursing [Online exclusive]. Oncology Nursing Forum, 32, E127-E138. doi:10.1188/05.ONF.E127-E138
67. Terpos, E., Christoulas, D., Kastritis, E., Katodritou, E., Kyrtsonis, M.C., Papanikolaou, X., Dimopoulos, M.A. (2008, June). Effect of lenalidomide-based regimens on bone remodeling in patients with relapsed/refractory multiple myeloma [Abstract 0192]. Presented at the European Hematology Association 13th Congress in Copenhagen, Denmark.
68. Terpos, E., Christoulas, D., Migkou, M., Gavriatopoulou, M., Papatheodorou, A., Eleutherakis-Papaiakouvou, E., Dimopoulos, M.A. (2009). Consolidation therapy with bortezomib, thalidomide, and dexamethasone (VTD) regimen after ASCT in myleoma patients who do not receive bisphosphonates reduces bone resorption and RANKL/OPG ratio but seems to have no effect on bone formation and angiogenesis [Abstract: 3863]. Retrived from http://ash.confex.com/ash/2009/webprogram/Paper18577.html
69. Terpos, E., & Dimopoulos, M.A. (2005). Myeloma bone disease: Pathophysiology and management. Annals of Oncology, 16, 1223-1231. doi:10.1093/annonc/mdi235
70. Tryciecky, E.W., Gottschalk, A., & Ludema, K. (1997). Oncologic imaging: Interactions of nuclear medicine with CT and MRI using the bone scan as a model. Seminars in Nuclear Medicine, 27, 142-151.
71. Vahtsevanos, K., Kyrgidis, A., Verrou, E., Katodritou, E., Triaridis, S., Andreadis, C.G., Antoniades, K. (2009). Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. Journal of Clinical Oncology, 27, 5356-5362. doi:10.1200/JCO.2009.21.9584
72. Weber, D.M. (2005). Solitary bone and extramedullary plasmacy-toma. Hematology, 1, 373-376.
73. Wick, J.Y. (2009). Spontaneous fracture: Multiple causes. Consultant Pharmacologist, 24, 100-102, 105-108, 110-102.
74. World Health Organization. (2009). WHO's pain ladder. Retrieved from http://www.who.int/cancer/palliative/painladder/en
75. Yeh, H.S., & Berenson, J.R. (2006). Treatment for myeloma bone disease. Clinical Cancer Research, 12(20, Part 2), 6279s-6284s. doi:10.1158/1078-0432.CCR-06-0681
76. Zou, W., Yue, P., Lin, N., He, M., Zhou, Z., Lonial, S., Sun, S.Y. (2006). Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clinical Cancer Research, 12, 273-280. doi:10.1158/1078-0432.CCR-05-0503